Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.51+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.92BP/E –Yield –
Trevi Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Trevi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$59.56M. For fiscal 2025 it was -$49.33M. The highest annual figure on record is -$18.41M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$49.33M | – |
| FY2024 | Dec 31, 2024 | -$51.52M | – |
| FY2023 | Dec 31, 2023 | -$33.92M | – |
| FY2022 | Dec 31, 2022 | -$29.91M | – |
| FY2021 | Dec 31, 2021 | -$32.48M | – |
| FY2020 | Dec 31, 2020 | -$32.49M | – |
| FY2019 | Dec 31, 2019 | -$26.65M | – |
| FY2018 | Dec 31, 2018 | -$18.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$20.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.22M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$11.91M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.05M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.56M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.66M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.19M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.64M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.65M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.42M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$4.96M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.38M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.14M | – |
See a number that looks wrong?